We highlight that hepatic IR and glucagon resistance at the AAs metabolism can putatively contribute to T2D development in NAFLD patients [53], and it might have clinical and therapeutic implications. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.